

Understanding Your Patient's Medical and Pharmacy Benefits



# **Indication and Important Safety Information**

#### Indication

Gamifant® (emapalumab-Izsg) is an interferon gamma (IFNy)-blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

# Important Safety Information Infections

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNy release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, *Pneumocystis jirovecii*, and fungal infections prior to Gamifant administration.

### **Increased Risk of Infection With Use of Live Vaccines**

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

#### **Infusion-Related Reactions**

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

#### **Adverse Reactions**

In the pivotal trial, the most commonly reported adverse reactions (≥10%) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastrointestinal hemorrhage, epistaxis, and peripheral edema.

Click here for full Prescribing Information for Gamifant.



## **Determining Medical vs Pharmacy Benefits**

When conducting a benefits investigation, it is important to include all of the information provided by the patient about their insurance. This includes the medical and pharmacy benefit information that is supplied on insurance cards. Some plans include pharmacy benefits along with the medical benefits, while other plans use a separate provider for pharmacy benefits called a pharmacy benefit manager.

This brochure provides examples to help your staff identify coverage for prescription drugs, like Gamifant® (emapalumab-lzsg), delivered in a healthcare setting.

### Gamifant will most likely be covered under the medical benefit

- Medical benefits typically cover drugs such as Gamifant that are administered by a healthcare provider at a facility such as a hospital.
- However, health plan requirements differ. Some plans may cover Gamifant under the pharmacy benefit.
- The benefits investigation will determine whether the health plan will cover Gamifant through your patient's medical or pharmacy benefit.
  - Gamifant Cares can assist with a benefits investigation. For more information, call Gamifant Cares at 1-833-597-6530 Monday through Friday, 8 AM to 8 PM ET.




It is important to verify your patient's benefits prior to each administration of Gamifant, especially if it is administered at a different site of care.

Please see Important Safety Information on page 2. <u>Click here</u> for full Prescribing Information for Gamifant.




### Insurance cards for commercially insured patients


### Some patients have 1 card for both the medical benefit and the pharmacy benefit



# Some patients with separate medical benefits and pharmacy benefits have 2 cards



room visits indicate the medical benefit.





Remember that patients can have more than 1 insurance plan. Be sure to ask the patient for all of his or her insurance cards. Make a copy of the front and back of each card for your patient records.

Please see Important Safety Information on page 2. <u>Click here</u> for full Prescribing Information for Gamifant.

